The company is committed to bringing its full breadth and depth to ensure health for people today and for future generations, leveraging extensive resources across the enterprise to innovate and execute with excellence. Management's objectives are guided by the company's credo and purpose, allowing employees to lead with agility and urgency. The competitive environment necessitates substantial investments in continuing research and development, which reflect management's commitment to creating life-enhancing innovations. The company invests significantly in research and development, with $12.2 billion allocated in 2020, aimed at delivering high-quality and innovative products. This investment is crucial for the development of new and innovative products, as well as for protecting the underlying intellectual property of the company's product portfolio, which is essential for success across all business areas. The company’s broad-based approach in human healthcare is designed to create value by developing accessible, high-quality, innovative products and services. The company has a diversified business model across the healthcare industry with flexibility designed into its manufacturing, research and development clinical operations, and commercial capabilities. The company continues to leverage its global manufacturing footprint and dual-source capabilities while closely monitoring and maintaining critical inventory to ensure adequate and effective distribution. The robust, active business continuity plans across the company's network have been instrumental in preparing the company for events like COVID-19, ensuring the ability to meet the majority of patient and consumer needs remains uninterrupted. The company’s high-quality credit rating allows superior access to financial capital markets, which is critical for funding operational needs, including investments in technology and innovation. The company has entered into contract manufacturing arrangements for vaccine production with third-party organizations, providing supplemental commercial capacity for vaccine production. The company remains focused on addressing the unmet needs of society and investing for an enduring impact, ultimately delivering value to its patients, consumers, healthcare professionals, employees, communities, and shareholders. The company’s strategic operations and resource allocation are overseen by the executive committee, which coordinates activities across its business segments. The company competes with other companies both locally and globally, with competition existing in all product lines, particularly in research involving the development and improvement of new and existing products and processes. The company’s commitment to creating value through partnerships and innovation is vital for transforming the firm into a competitive force. The company’s IT capabilities are integral to mobilizing and deploying IT-based resources in combination with leveraging the value of other resources and capabilities, which is essential for supporting business needs and enhancing operational efficiency. The company’s strategic management practices emphasize the importance of aligning technology resources with business strategies to optimize performance and drive growth.